INTRAOCULAR TUMORS(1)
Choroidal Melanoma
M. Akhlaghi MDAssociate professor of Isfahan university of medical science
Feiz Hospital
2
INTRAOCULAR TUMORS
• Intraocular tumors of childhood• Intraocular tumors in adults• Vascular tumors
3
INTRAOCULAR TUMORSI. Intraocular tumors of childhoodA. Retinal tumors
Retinoblastoma
B. Iris and ciliary body lesionsMedulloepithelioma
C. Choroidal and RPE lesionsCongenital hypertrophy of the retinal pigment epitheliumCombined hamartoma of the retina and retinal pigment epitheliumCongenital melanocytosis
D. Other benign tumors
4
INTRAOCULAR TUMORSII. Intraocular tumors in adultsA. Choroidal and RPE lesions
Choroidal nevusChoroidal melanoma
B. Iris and ciliary body lesionsFuchs adenomaIris nevusCiliary body nevusIris melanomaCiliary body melanoma
C. Metastatic disease to the choroid
5
INTRAOCULAR TUMORS
• III. Vascular tumorsA. Retinal capillary hemangiomaB. Retinal cavernous hemangiomaC. Choroidal hemangioma
6
INTRAOCULAR TUMORS
Common Malignancies • Metastatic tumors are the most common
intraocular malignancy
• Choroidal melanoma is the most common primary malignant intraocular tumor
• Retioblastima is the most common malignancy in chailhood
7
CHOROIDAL MELANOMA
8
CHOROIDAL MELANOMA Etiology
• Develop from preexisting melanocytic nevi
• De novo growth
9
CHOROIDAL MELANOMAEpidemiology
• Incidence: about 5-7 cases per 1 million population
• Incidence of choroidal melanoma is highest around age 60 years
10
CHOROIDAL MELANOMA
Risk FactorsPredisposing factors:
• uveal nevus Estimated rate of malignant transformation is 1 in 5000/year
• dysplastic nevus syndrome
• Ocular or oculodermal melanocytosis [nevus of ota]. The incidence of choroidal melanoma in oculodermal melanocytosis is 1 in 400
• family history of uveal melanoma Despite a few reports of sporadic family clusters, most patients with posterior uveal melanoma have no known family history of the disease.
11
CHOROIDAL MELANOMA
Risk Factors cont.
• Age• Gender • Race • Eye color• Sun light exposure• Smoking• Mobile use
12
CHOROIDAL MELANOMA
Clinical Presentation
• Choroidal melanomas remain asymptomatic for prolonged periods of time.– The more anterior their origin, the longer the delay of any
symptoms. • Choroidal melanoma symptoms:
– Blurred visual acuity…– Paracentral scotoma…– Painless and progressive visual field loss…– Floaters…– Severe ocular pain…
13
• Anterior choroidal melanomas might show sentinel vessels that feed the metabolically active tumor
14
CHOROIDAL MELANOMA
Clinical Presentation
• small subconjunctival area of abnormal hyperpigmentation due to transscleral growth of an anterior choroidal melanoma
15
CHOROIDAL MELANOMA
Clinical Presentation
CHOROIDAL MELANOMA
Diagnostic EvaluationIndirect ophthalmoscopy • Ophthalmoscopy is typically adequate for
diagnosis. Ultrasound, CT, MRI and FA can be used to aid in diagnosis,
16
CHOROIDAL MELANOMA
Diagnostic Evaluation• Ophthalmologic examination may reveal the following:
• Small choroidal melanomas typically take the form of a nodular, dome-shaped, and well-circumscribed mass under the retinal pigment epithelium
17
• As choroidal melanomas grow, they may adopt more irregular configurations (mushroom shapes)
18
CHOROIDAL MELANOMA
Diagnostic Evaluation
• Diffuse choroidal melanoma, characterized by lateral growth throughout the choroid with minimal elevation, are more difficult to diagnose and often cause significant exudative retinal detachment
19
CHOROIDAL MELANOMA
Diagnostic Evaluation
• Choroidal melanoma may remain undetected underneath a large exudative retinal detachment, a subretinal hemorrhage, or a vitreous hemorrhage
20
CHOROIDAL MELANOMA
Diagnostic Evaluation
• Choroidal melanomas may have variable coloration, ranging from amelanotic to darkly pigmented; some are partially pigmented
21
CHOROIDAL MELANOMA
Diagnostic Evaluation
CHOROIDAL MELANOMA
Diagnostic Evaluation• Overlying the choroidal melanoma, there are usually
retinal pigment epithelial changes (eg, drusen), patches of atrophy, and orange discoloration; orange changes can occur in both malignant and benign lesions
22
CHOROIDAL MELANOMA
Diagnostic Evaluation
• Ultrasonography• Choroidal melanoma characteristically shows an
initial prominent spike, followed by low-to-medium internal reflectivity with diminishing amplitude
23
24
CHOROIDAL MELANOMA
Diagnostic EvaluationAngiography• Fluorescein angiography and indocyanine green
angiography do not show pathognomonic signs of choroidal melanoma but can help point to its diagnosis
• Small choroidal melanomas may show fluorescein angiographic changes similar to some choroidal nevi, (ranging from normal angiography to hypofluorescencesecondary to blockage)
• Larger melanomas may show a patchy pattern of early hypofluorescence and hyperfluorescence followed by late intense staining
25
CHOROIDAL MELANOMA
Diagnostic Evaluation
FA typically shows mottled fluorescence during the arteriovenousphase and then progressive leakage and staining
26
Choroidal MelanomaDiagnostic Evaluation
ICG provides more information about the extent of the tumour, because there is less interference caused by RPE changes
27
Choroidal MelanomaDiagnostic Evaluation
Choroidal melanoma, transillumination shadow
28
CHOROIDAL MELANOMA
Diagnostic Evaluation• MRI of the globe and orbit can be used to determine
extrascleral extension of the melanoma and distinguish surrounding fluid from the tumor
29
CHOROIDAL MELANOMA
Differential DiagnosisThe differential diagnosis for pigmented lesions in the ocular fundus most commonly includes the following:
• choroidal nevus • atypical disciform scar associated with AMD• suprachoroidal hemorrhage • RPE hyperplasia• congenital hypertrophy of the retinal pigment epithelium (CHRPE)• choroidal hemangioma with RPE hyperpigmentation• Melanocytoma• metastatic carcinoma with RPE hyperpigmentation• choroidal osteoma
30
Choroidal Melanoma Differential Diagnosis
Differential Diagnosis of Amelanotic Choroidal Mass
• Amelanotic melanoma• Choroidal metastasis• Choroidal hemangioma• Choroidal osteoma• Age-related macular or
extramacular degeneration• Choroidal detachment• Uveal effusion syndrome• Posterior scleritis• Chorioretinal granuloma
• Toxoplasmic retinochoroiditis• Rhegmatogenous retinal
detachment• Degenerative retinoschisis• Presumed acquired retinal
hemangioma• Neurilemoma• Leiomyoma• Retinal cavernous hemangioma• Combined hamartoma of the
retinal pigment epithelium
31
Large choroidal naevus Metastatic tumour Localized choroidalhaemangioma
Choroidal detachment Choroidal granuloma Dense sub-retinal orsub-RPE haemorrhage32
CHOROIDAL MELANOMA
Differential DiagnosisNevus vs. melanoma• Virtually all choroidal melanocytic tumors thicker than
3 mm are melanomas, and virtually all choroidal melanocytic lesions thinner than 1 mm are nevi
• Many lesions 1-2 mm in thickness may be benign, although the risk of malignancy increases with height
• Flat lesions with a basal diameter of 10 mm or less are almost always benign.
33
CHOROIDAL MELANOMA
Differential DiagnosisNevus vs. melanomaClinical risk factors for enlargement of choroidal melanocytic lesions:
• Clinical symptoms such as metamorphopsia, photopsia, visual field loss• absence of drusen or RPE changes• presence of orange pigmentation• associated subretinal fluid• larger size at presentation• juxta papillary location• hot spots on fluorescein photography • documented increase of 0.3 mm in thickness and 0.5 mm in basal
diameter
34
Typical choroidal nevus• Common - 2% of population
• Round slate-grey withindistinct margins
• Surface drusen
• Flat or slightly elevated
• Diameter less than 5 mm
• Location - anywhere
• Asymptomatic
35
Suspicious choroidal naevus• Diameter more than 5 mm
• Elevation 2 mm or more
• Surface lipofuscin
• Posterior margin within3 mm of disc
• May have symptoms dueto serous fluid
36
• The recommended management of choroidal nevi is photographic documentation for lesions less than 1 mm in thickness and photographic and ultrasonographic documentation for lesions greater than 1 mm in thickness, coupled with regular, periodic reassessment for signs of growth.
• Uveal Nevus estimated rate of malignant transformation is 1 in 5000/year (Rayan: However, the available literature suggests that the risk of choroidal and ciliary body melanomas associated with nevi of the uveal tract is low. Each year, only 1 in 5000 persons with such nevi develop a melanoma. with these conditions, current guidelines and recommendations for management and follow-up may not be cost-effective
37
CHOROIDAL MELANOMA
Classification The modified Callender classification of uveal melanomas:
• spindle cell nevus• spindle cell melanoma • epithelioid melanoma• mixed-cell type
This classification can only be used in cases in which the eye has been removed
38
CHOROIDAL MELANOMA
Classification Classification based on size:
• Small: <10 mm in diameter and <3 mm in height
• Medium: 10–15 mm in diameter and 3–5 mm in height
• Large: >15 mm in diameter and >5 mm in height
39
genetic melanoma type
• It was discovered that uveal melanomas tend to develop several non-random chromosomal abnormalities, particularly chromosome 3 loss (monosomy-3) and gains in 6p and 8q…..
40
CHOROIDAL MELANOMA
Classification
Metastatic Evaluation• The Collaborative Ocular Melanoma Study (COMS)
reported an incidence of metastatic disease of 25% at 5 years after initial treatment and 34% at 10 years
• clinically evident metastatic disease at the time of initial presentation can be detected in less than 2% of patients
• It is now known that micrometastases may occur several years before the diagnosis of a choroidal melanoma
• In general, survival with metastatic uveal melanoma is poor, with a median survival of less than 6 months
41
• An assessment of metastatic disease patterns in COMS revealed liver involvement in 89% , lung involvement in 24%, bone involvement in 17%, and skin and subcutaneous tissue involvement in 12%.
• In cases that were autopsied, liver involvement was found in 100% and lung involvement in 50% of the patients with metastatic disease.
42
CHOROIDAL MELANOMA
Metastatic Evaluation
All patients require metastatic evaluation prior to definitive treatment of the intraocular melanoma
why?
• To rule out the possibility of detectable metastatic melanoma If metastatic disease is clinically present during the pretreatment evaluation of the eye tumor, enucleation is inappropriate unless the eye is painful.
• To determine whether the patient has any other medical conditions For example, the COMS found preexisting independent primary cancers in about 10% of patients
43
CHOROIDAL MELANOMA
Metastatic Evaluation
metastatic evaluation should be performed on all patients on a yearly follow-up basis and should include:
• comprehensive physical examination• liver function tests• Chest x-ray, although its yield was found to be low.
• Liver imaging studies: Ultrasound of the abdomen is usually sufficient
44
CHOROIDAL MELANOMA
Metastatic Evaluation
CHOROIDAL MELANOMA
ManagementThe methods of patient management currently in use depend on several factors:• size, location, and extent of the tumor• visual status of the affected eye and of the
fellow eye, age and general health of the patient
45
Observation may be acceptable for posterior uveal tumors where • diagnosis is not well established; in particular, tumors
of less than 2 mm in elevation and 10 mm in diameter
• in very elderly and systemically ill patients who are not candidates for any sort of therapeutic intervention
46
CHOROIDAL MELANOMA
Management
• Enucleation is the classic approach for some medium-sized, many large, and all extra-large choroidal melanomas and complicated tumors, which compromise visual function and for which other therapies tend to fail
47
CHOROIDAL MELANOMA
Management
Plaque brachytherapy is probably the most common method of treating uveal melanoma• brachytherapy is a widely accepted alternative to
enucleation for medium-sized posterior uvealmelanomas
• iodine 125 is the isotope most frequently used• local tumor control rates to as high as 96%.• Regrowth: 4%-5% • Late radiation complications: optic neuropathy and
retinopathy, are visually limiting in as many as 50% of patients
48
CHOROIDAL MELANOMA
Management
49
Charged-particle radiation (proton beam radiotherapy)• High -linear-energy transfer radiation with charged particles
(protons and helium ions) has been used effectively in managing and choroidal melanomas.
• The technique requires surgical attachment of tantalum clips to the sclera to mark the basal margins of the tumor prior to the first radiation fraction. The charged-particle beams deliver a more homogeneous dose of radiation energy to a tumor than does a radioactive plaque, and the lateral spread of radiation energy from such beams is less extensive
• Local tumor control rates of up to 98% have been reported. • Radiation complications, most commonly anterior, lead to
uncontrolled neovascular glaucoma in 10% of treated eyes and vision loss in approximately 50%.
50
CHOROIDAL MELANOMA
Management
51
52
CHOROIDAL MELANOMA
Management
• External beam irradiation Conventional external-beam radiation therapy is ineffective as a single-modality treatment for malignant melanoma.
53
CHOROIDAL MELANOMA
Management
• Pars plana vitrectomy endoresection
54
CHOROIDAL MELANOMA
Management
A 37-year-old woman treated by endoresection. (A) Left eye before treatment, with visual acuity of 20/20 . (B) Fundus appearance 10 years later
• Block excision (sclerouvectomy) is an alternative treatment method reserved for small tumors covering less than one third of the globe’s circumference
55
CHOROIDAL MELANOMA
Management
56
• Laser photocoagulation and transpupillarythermotherapy (TTT) are used to treat selected small choroidal melanomas that are located away from the fovea and are less than 3 mm in thickness
• Orbital exenteration is a radical treatment reserved for cases with widespread orbital extension; it should be considered only in rare cases where marked discomfort is associated with massive orbital spread of the melanoma
57
CHOROIDAL MELANOMA
Management
• Adjuvant systemic chemotherapy is not advocated
• When distant metastases are found in the initial systemic workup, palliative systemic chemotherapy is the primary treatment
58
CHOROIDAL MELANOMA
Management
59